Zealand Pharma’s Post

Ozempic, celebs, and the obesity battle: who’s going to win? In the race to dominate the obesity treatment market, Eli Lilly and Company and Novo Nordisk are competing head-to-head—and their stocks are skyrocketing as a result. With celebrities using Novo’s Ozempic/ Wegovy and Lilly’s Mounjaro to manage their weight, the battle for market share is heating up amid some headwinds through RFK Jr.’s potential appointment to lead the U.S. Department of Health and Human Services (HHS). Apart from Ozempic being a popular choice right now, something else is also giving Novo an edge. I believe that Novo takes a more purpose-driven approach, building on their legacy expertise ecosystem orchestration around diabetes (“Cities Changing Diabetes”). Now, they revamped the platform as “Cities for a better health” (https://lnkd.in/ex2mFbwW). This program tackles the root causes of obesity through prevention, fostering healthier lifestyles, and collaborations with healthcare professionals. By tackling broader health challenges and focusing on prevention, not just treatment, Novo positions itself as a problem-solver, while others in the space might be seen as problem/symptom-managers. What do you think? Let’s chat!

Partnerships. That’s one of our core pillars in the Novo Nordisk Transformational Prevention Unit (TPU), where we explore science-based solutions to prevent obesity.   Today, I am happy to share that the TPU Novo Nordisk has kicked-off a research partnership with Phenomix Sciences, a biotech company.   Through an in-depth study of people living with obesity, Phenomix Sciences have proposed a precision medicine approach to obesity. How does this approach work? It uses newly identified sub-groups of obesity to find the underlying causes and link this to a more tailored way to tackle the disease. In our research collaboration, we will explore whether we can apply such a precision medicine approach to obesity prevention and predict the predisposition to specific sub-groups of obesity.   This partnership is just the start of our journey, and while there are still many unknowns to address before we achieve a solution, it represents a step forward in our mission to help halt the global rise of obesity. We will continue to look for and build innovative partnerships to drive change to defeat serious chronic diseases like obesity. #PrecisionMedicine #Prevention #Innovation #Partnerships

AMRA is Gearing Up For ObesityWeek® 2024! We’re excited to see you all in San Antonio, TX  for The Obesity Society’s 2024 edition of ObesityWeek®, which is set to kick off this Sunday! ObesityWeek®, which runs until November 6, is the global home of the latest developments in evidence-based obesity science. The event brings together researchers, clinicians, drug developers, and policy experts to help move the obesity field forward, and AMRA is proud to share our latest findings in the field at this important event. AMRA researchers will be presenting results from a recent study that unraveled hidden weight gain, adverse muscle composition, and cardiometabolic risk increases in antidepressant users. The study, which is part of the CoMorMent Initiative, was recently published in Obesity as an “Editor’s Choice” piece. You can learn more about the study by finding our poster no. 133 titled ‘Hidden Weight Gain, Adverse Muscle Composition and Cardiometabolic Risks in Antidepressant Users’ during the session on November 3rd at 07.30 CDT. Come connect with us at OW2024, or reach out to us at info@amramedical.com to learn more. We hope to see you in the Lone Star State next week! #AMRAMedical #OW2024 #goteamAMRA #bodycomposition #musclecomposition #obesity #weightloss #GLP1 #clinicaltrials #CoMorMent

🚨 A Wake-Up Call on Alcohol and Breast Cancer 🚨 We often become desensitized to powerful scientific findings, but let’s pause and truly reflect on this: Imagine sitting across from someone living with breast cancer. Imagine asking them, “If you could go back and do one thing to reduce your risk, what would you do?” Wouldn’t they say, “Anything. Everything.” The latest research, in collaboration with WHO/Europe and IARC, delivers a message we can no longer ignore: There is no safe level of alcohol consumption when it comes to breast cancer risk. 🍷 It’s not about the type of drink 1️⃣ Even one drink per day can significantly elevate the risk. 🎗️ The dose-response is clear: the more you drink, the higher the risk. This isn’t just a statistic; it’s a call to action. A reminder that prevention isn’t about sacrifice. it’s about empowerment. It’s about taking informed steps today to protect the tomorrows we hold dear.

Revolution in Obesity Treatment on the Horizon? 🚀 Exciting developments in healthcare as Roche's strategic acquisition of Carmot Therapeutics starts to bear fruit! Their hopeful contender in the obesity market, CT-388, is showing promising results. Breaking down the first clinical data since the $2.7 billion investment, CT-388 has demonstrated an impressive 18.8% average weight loss, surpassing current market front-runners. It's not just about shedding pounds; all participants experienced over 5% weight loss, with almost half surpassing the 20% milestone. 💉📉 What does this mean for the industry? We're looking at a potential game-changer in both obesity and diabetes care. With weight loss and blood sugar level improvements notable in the study, CT-388's dual-action therapy steps up as a serious contender for best-in-class treatment. This innovation doesn't just signify a win for Roche but also for patients seeking more effective treatments in the battle against obesity and its associated risks. Keep an eye on CT-388 as it progresses, poised to transform lives and the market landscape. 💊🔬 #HealthcareInnovation #ObesityTreatment #DiabetesCare #ClinicalData

Obesity, a complex chronic disease characterized by the excessive accumulation of fat, represents one of the major challenges for public health worldwide. In the year 2022, 1/8 of the world population was affected by it. NAD+, which is a main player in energy metabolism, has been demonstrated to be closely related with obesity, and strategies to boost NAD+ levels proved to protect from obesity in animal models. Learn more: https://lnkd.in/dbYYADEt 🔍 Author: Raúl Pérez Mato #NADIS #NAD #NAD_and_obesity

In the realm of precision medicine, which typically concentrates on highly specialized downstream targets, we at Resalis differentiate ourselves with a unique approach. Obesity is a complex and multifaceted disease that has consistently defied downstream treatments. That's where miR-22 comes in as an upstream target. By affecting a range of pathways involved in obesity, miR-22 offers a broader yet distinct approach to tackling this complex condition. Targeting miR-22 is analogous to addressing the root cause rather than just the symptoms, as our strategy aims to impact the plethora of underlying pathways of obesity to offer a more comprehensive treatment option. Resalis is at the forefront of this innovative approach, underscoring the significance of thoroughly understanding biological networks in obesity management.

During the last couple of days Embla's unique research has been displayed at the European Congress on Obesity (ECO) 2024 in Venice, and described on a number of global media platforms. The Mirror: https://lnkd.in/dhVE3C_S The Standard: https://lnkd.in/dxtyB7ua Perspective Media: https://lnkd.in/d3BAJAqV Our results show that patients can achieve approximately 15% weight loss when our digital service is combined with the use of semaglutide. The weight loss was achieved using only around one third of the usually applied semaglutide dose and that this is achievable regardless of patients initial BMI and the amount of semaglutide used. Moreover, our results show that continuous support through our digital platform (including support from mentors, nurses and physicians) enables tapering of semaglutide while maintaining the achieved weight loss. Henrik Rindel Gudbergsen Kine Stamp-Larsen Jesper Søndergaard Pedersen European Association for the Study of Obesity (EASO)

We all value the health and well-being of women in our families and communities highly, and we share the responsibility to protect future generations from preventable diseases. But breast cancer threatens the health of women. It is the most common cancer globally. And it a makes up a quarter of all cancers in women and its impact continues to grow. This situation is made worse by low levels of awareness about major risk factors — such as alcohol consumption — is still low, and politicians don't yet fully use prevention strategies. Alcohol companies are fueling these problems, for example through targeted aggressive alcohol marketing to women, to accelerate alcohol use in women, putting them at greater breast cancer risk. Alcohol companies and their lobby groups are also misleading people about the cancer risk of their products, causing doubt and confusion. Independent, world class science has proven that even low dose alcohol consumption significantly increases the risk of breast cancer. But politicians have the tools to prevent breast cancer cases and deaths. Alcohol policy actions, such as raising alcohol taxes and implementing clear cancer warning labels, can significantly reduce alcohol consumption and breast cancer risk. By taking these steps, we can promote women’s health and save lives. For #BreastCancerAwarenessMonth - here is what we know and what can be done about the commercial determinants of breast cancer. 6 Reasons Why New WHO Comment on Health and Cancer Risks From Low Dose Alcohol Use Is a Game Changer, via Kristina Sperkova https://lnkd.in/dPF3bu35 World Health Organization: No Level of Alcohol Use Is Safe for our Health, via Carina Ferreira-Borges https://lnkd.in/dm7MkXrZ #AlcoholHarms #BreastCancer #Cancer #CancerPrevention #AlcoholPolicy #AlcoholTaxation #AlcoholAwareness

This year, we are participating in ObesityWeek® 2024 in San Antonio, Texas. This annual meeting serves as a crucial platform for advancing our understanding and treatment of obesity, which is a global health challenge with significant medical and social implications. At Zone.Health, we're deeply committed to tackling obesity through innovative research and solutions. We have three research papers being presented and published in the prestigious Journal of Obesity this week! These studies delve into critical areas of obesity research, and we're excited to share our findings with you throughout the week. Here's a sneak peek at the topics: •⁠ ⁠𝐒𝐭𝐮𝐝𝐲 𝟏: Effectiveness of the Zone.health program on Fatty Liver Improvements •⁠ ⁠𝐒𝐭𝐮𝐝𝐲 𝟐: Effectiveness of a Hybrid Approach for Cardiovascular Risk Reduction •⁠ ⁠𝐒𝐭𝐮𝐝𝐲 𝟑: Effectiveness of Tirzepatide vs. Semaglutide in a Hybrid Weight Loss Program We'll post detailed summaries of each study throughout the week, outlining the key findings and their potential significance in the fight against obesity. #HealthcareInnovation #MetabolicHealth #LiverDisease #ObesityManagement #ZoneHealth #GLP1 Ihsan Almarzooqi - Ali Hashemi - Zeina A. - Hala Zakaria - meta[bolic] - GluCare.Health